Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review

被引：22

作者：

King, Jordan B. ^{[1
]}

Bress, Adam P. ^{[1
,2
]}

Reese, Austin D. ^{[1
]}

Munger, Mark A. ^{[1
,3
]}

机构：

[1] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA

[2] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA

[3] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA

来源：

PHARMACOTHERAPY | 2015年 / 35卷 / 09期

关键词：

heart failure with reduced ejection fraction; systolic heart failure; neprilysin inhibition; therapeutic review; pharmacotherapy; CONVERTING-ENZYME-INHIBITORS; NEUTRAL ENDOPEPTIDASE INHIBITOR; VENTRICULAR SYSTOLIC FUNCTION; NATRIURETIC PEPTIDES; RANDOMIZED TRIAL; MORBIDITY; MORTALITY; LCZ696; CANDESARTAN; ENALAPRIL;

D O I：

10.1002/phar.1629

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There has been a 10-year hiatus in the approval of a new pharmacotherapy for patients with chronic heart failure with a reduced ejection fraction (HFrEF). Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. This has resulted in the development of a new agent, LCZ696. A comprehensive overview of LCZ696, its pharmacology, its role in the pathophysiology of HFrEF, completed and future clinical trial information, specific critical issues, and the place of LCZ696 in HFrEF therapy are presented.

引用

页码：823 / 837

页数：15

共 80 条

[1] NEUTRAL ENDOPEPTIDASE INHIBITION INCREASES THE URINARY-EXCRETION AND PLASMA-LEVELS OF ENDOTHELIN [J].

ABASSI, Z ;

GOLOMB, E ;

KEISER, HR .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (07) :683-685

[2] Calculating the number needed to treat for trials where the outcome is time to an event [J].

Altman, DG ;

Andersen, PK .

BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495

[3]

[Anonymous], 2014, AM HEART ASS EMERGIN

[4]

Ayalasomayajula SP, 2014, AM COLL CLIN PHARM A

[5]

Ayalasomayajula S, 2013, HYPERTENSION, V62

[6]

Ayalasomayajula S, 2013, HYPERTENSION, V62

[7]

Califf RM, 2014, EUR HEART J

[8] Heart failure - A state of brain natriuretic peptide deficiency or resistance or both! [J].

Chen, Horng H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (10) :1089-1091

[9] Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review [J].

Clerico, A ;

Emdin, M .

CLINICAL CHEMISTRY, 2004, 50 (01) :33-50

[10]

Cohn J N, 1997, J Card Fail, V3, P173, DOI 10.1016/S1071-9164(97)90013-0

← 1 2 3 4 5 6 7 8 →